Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 238,152 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 238,152 shares of the business’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $68.39, for a total value of $16,287,215.28. Following the completion of the sale, the chief executive officer directly owned 161,848 shares of the company’s stock, valued at $11,068,784.72. The trade was a 59.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Performance

TEM traded up $2.21 during trading on Thursday, hitting $70.69. 6,571,301 shares of the stock were exchanged, compared to its average volume of 7,384,247. The stock has a fifty day moving average price of $54.37 and a two-hundred day moving average price of $51.71. The firm has a market capitalization of $12.75 billion, a P/E ratio of -49.09 and a beta of 3.58. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $104.32. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10. The company had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. Tempus AI’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same period last year, the firm posted ($0.22) EPS. As a group, sell-side analysts predict that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TEM has been the topic of a number of research analyst reports. Lake Street Capital downgraded Tempus AI to a “hold” rating in a research report on Monday, July 20th. Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a report on Friday, July 31st. Piper Sandler lowered their target price on Tempus AI from $58.00 to $56.00 and set a “neutral” rating for the company in a research note on Tuesday, August 4th. Finally, HC Wainwright dropped their price target on shares of Tempus AI from $64.00 to $56.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. Nine research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $65.69.

Institutional Investors Weigh In On Tempus AI

Institutional investors and hedge funds have recently made changes to their positions in the company. JPL Wealth Management LLC bought a new stake in Tempus AI during the third quarter valued at $26,000. Los Angeles Capital Management LLC bought a new stake in Tempus AI in the 4th quarter valued at about $27,000. EMC Capital Management bought a new position in shares of Tempus AI in the second quarter valued at approximately $29,000. Harvest Fund Management Co. Ltd bought a new stake in Tempus AI during the third quarter worth approximately $38,000. Finally, Whittier Trust Co. lifted its position in Tempus AI by 190.0% in the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after purchasing an additional 570 shares during the period. 24.22% of the stock is owned by institutional investors and hedge funds.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.